Alpelisib, Fulvestrant and Dapagliflozin for the Treatment of HR+, HER2 -, PIK3CA Mutant Metastatic Breast Cancer
Status: UNKNOWN
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer|HER2-negative Breast Cancer
Interventions: DRUG: Dapagliflozin 10Mg Tab
Sponsor: Saint Luke's Health System
Collaborators: Novartis Pharmaceuticals